Arbutus Biopharma
ABUS
ABUS
51 hedge funds and large institutions have $61.1M invested in Arbutus Biopharma in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less capital invested
Capital invested by funds: $ → $
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
Holders
51
Holding in Top 10
–
Calls
$470K
Puts
$560K
Top Buyers
| 1 | +$1.42M | |
| 2 | +$870K | |
| 3 | +$347K | |
| 4 |
Morgan Stanley
New York
|
+$206K |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$118K |
Top Sellers
| 1 | -$737K | |
| 2 | -$691K | |
| 3 | -$609K | |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$538K |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$516K |